Regeneron Pharmaceuticals Stock

$546.10

1.48% today

Nasdaq, Jul 08, 03:46 pm CET

ISIN

US75886F1075

Symbol

REGN

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Regeneron Pharmaceuticals Stock price

$538.11

-102.77 16.04% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-9.25 1.69%

ISIN

US75886F1075

Symbol

REGN

Reports

Quarter | Annual

Index

NASDAQ-100, S&P 500

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$58.1b

Enterprise Value

$52.5b

Net debt

positive

Cash

$8.3b

Shares outstanding

108.2m

Valuation (TTM | estimate)

P/E

13.3 | 14.8

P/S

4.1 | 4.3

EV/Sales

3.7 | 3.8

EV/FCF

17.7

P/B

2.0

Financial Health

Equity Ratio

77.7%

Return on Equity

15.0%

ROCE

12.0%

ROIC

13.2%

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

$14.1b | $13.7b

EBITDA

$4.6b | $4.4b

EBIT

$4.1b | $4.0b

Net Income

$4.5b | $3.9b

Free Cash Flow

$3.0b

Growth (TTM | estimate)

Revenue

7.5% | -3.8%

EBITDA

0.7% | -5.5%

EBIT

-0.7% | -5.8%

Net Income

16.6% | -11.0%

Free Cash Flow

-24.6%

EPS

$40.5

FCF per Share

$27.4

Short interest

2.0%

Employees

15k

Rev per Employee

$940.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

24x Buy

71%

9x Hold

26%

More details on Analyst Estimates Including Price Targets

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy

71%

Hold

26%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	14,086 14,086	8% 8% 100%
- Direct Costs	1,875 1,875	11% 11% 13%
Gross Profit	12,211 12,211	7% 7% 87%
- Selling and Administrative Expenses	3,053 3,053	12% 12% 22%
- Research and Development Expense	5,057 5,057	10% 10% 36%
EBITDA	4,559 4,559	1% 1% 32%
- Depreciation and Amortization	496 496	14% 14% 4%
EBIT (Operating Income) EBIT	4,064 4,064	1% 1% 29%
Net Profit	4,499 4,499	17% 17% 32%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Regeneron Pharmaceuticals Stock News

Neutral

The Motley Fool

●

3 days ago

2 Beaten-Down Stocks to Buy and Hold

Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Positive

WSJ

●

6 days ago

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Positive

Reuters

●

6 days ago

US FDA approves Regeneron's blood cancer therapy

The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.

More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office	United States
CEO	Leonard Schleifer
Employees	15,158
Founded	1988
Website	www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now